Anne P. O'Dea, MD

Professional Background

Dr. Anne O'Dea is certified by the American Board of Internal Medicine with subcertification in hematology and medical oncology. She completed a fellowship at the University of Kansas Medical Center. She earned her medical degree from the University of Kansas School of Medicine and completed her residency at the University of Kansas Medical Center.

• BGS, Human Biology, University of Kansas
• MD, Medicine, University of Kansas-Medical Center
• Residency, Internal Medicine, University of Kansas School of Medicine, Kansas City, KS
• Post Doctoral Fellowship, Hematology and Oncology, University of Kansas School of Medicine, Kansas City, KS
• Post Doctoral Fellowship, Breast Oncology, University of Kansas School of Medicine, Kansas City, KS

• ABIM Certification in Hematology, American Board of Internal Medicine
• ABIM Certification in Internal Medicine, American Board of Internal Medicine
• ABIM Certification in Medical Oncology, American Board of Internal Medicine
• Kansas Medical License, Kansas Board of Healing Arts

• Southwest Oncology Group, Breast Cancer Survivorship and Prevention and Epidemiology Committee, Member, 2017 - Present
• University of KS Cancer Center, Breast Disease Working Group, Member, 2017 - Present
• Accreditation Council for Graduate Medical Education, Fellowship Milestones Committee, Member, 2016 - 2019
• Southwest Oncology Group, Southwest Oncology Group, Member, 2015 - Present
• American College of Surgeons, Commission on Cancer Committee, Member, 2014 - 2017
• American Society of Clinical Oncology, Member, 2007 - Present

---

• Randomized Phase II Trial of Fulvestrant or Exemestane With or Without Ribociclib After Progression on Anti-Estrogen Therapy Plus Cylin-Dependent Kinase 4/6 Inhibition in Patients with Unresectable or Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer (MAINTAIN Study), Columbia University Medical Center. Clinical Trial, HSC #144455
• Understanding and Predicting Breast Cancer Events after Treatment (UPBEAT), National Cancer Institute/National Heart Lung Blood Institute - Clinical Trial HSC#144677
• PROspective Evaluation of Germline Mutations, Cancer Outcomes and Tissue Biomarkers (P.R.O.G.E.C.T.), University of Kansas Medical Center (KU IRB #140761) Registry, HSC 12614
• Phase 2 Window Study of Two Dose Levels of SAR439859 (SERD) Versus Letrozole in Newly Diagnosed Pre-operative Post-menopausal Patients with ER+ HER2- Primary Breast Cancer (the "Study"), Sanofi - Clinical Trial HSC #145320

• Griffiths JasonI, Chen Jinfeng, Cosgrove PatrickA, O'Dea AnneP, Sharma Priyanka, Ma Cynthia, Trivedi Meghna, Kalinsky Kevin, Wisinski KariB, O'Regan Ruth, Makhoul Issam, Spring LauraM, Bardia Aditya, Adler FrederickR, Cohen AdamL, Chang JeffreyT, Khan QamarJ, Bild AndreaH. 2021. Serial Single-Cell Genomics Reveals Convergent subclonal Evolution of Resistance as Patients with Early-Stage Breast Cancer Progress on Endocrine Plus CDK4/6 Therapy. Nature Cancer, 2 (6), 658-671
• Sharma Priyanka, Kimler BruceF, O'Dea AnneP, Nye LaurenE, Wang Yen, Yoder Rachel, Staley Joshua, Prochaska Linda, Wagner Jamie, Amin Amanda, Larson Kelsey, Balanoff Christa, Elia Manana, Crane Gregory, Madhusudhana Sheshadri, Hoffmann Mark, Sheehan Maureen, Rodriguez Roberto, Finke Karissa, Shah Rajvi, Satelli Deepti, Shrestha Anuj, Beck Larry, McKittrick Richard, Pluenneke Robert, Raja Vinay, Venkatadri Beeki, Corum Larry, Heldstab Jaimie, LaFever Stephanie, Prager Micki, Phadnis Milind, Mudaranthakam DineshPal, Jensen Roy, Godwin Andrew, Salgado Roberto, Mehta Kathan, Khan Qamar. 2021. Randomized Phase II Trial of Anthracycline-Free and Anthracycline-Containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I-III Triple-Negative Breast Cancer (NeoSTOP). Clinical Cancer Research, 27 (4), 975-982
• Sharma Priyanka, Abramson Vandana, O'Dea Anne, Nye LaurenE, Mayer Ingrid, Pathak Harsh, Hoffmann Marc, Stecklein Shane, Elia Manana, Lewis Sharon, Scott Jecinda, De Jong Jilliann, Wang Yen, Yoder Rachel, Schwensen Kelsey, Finke Karissa, Heldstab Jaimie, LaFaver Stephanie, Williamson Ste, Phadnis Milind, Reed Gregory, Kimler BruceF, Khan QamarJ, Andrew. 2021. Clinical and Biomarker Results from Phase I/II Study of P13K Inhibitor Alpellsib Plus Nab-Paclitaxel in HER2-Negative Metastatic Breast Cancer. Clinical Cancer Research, 27 (14), 3896-3904
• Larson KelseyE, Wang YenY, Finke Karissa, Yoder Rachel, Schwensen Kelsey, O'Dea AnneP, Khan QamarJ, Nye LaurenE, Heldstab Jaimie, Godwin AndrewK, Kimler BruceF, Sharma Priyanka. 2020. Impact of Germline BRCA Mutation Status on Survival in Women with Metastatic Triple Negative Breast Cancer. Journal of Cancer Treatment and Research, 7, 81-86
• Sharma Priyanka, Kimler BF, O'Dea AnneP, Nye LaurenE, Wang YY, Yoder R, Prochaska LH, Wagner JL, Amin AL, Larson K, Balanoff C, Elia M, Crane GJ, Madhusudhana S, Hoffmann MS, Sheehan M, Rodriguez RR, Jensen RoyA, Godwin AndrewK, Khan QamarJ. 2019. Results of randomized phase II trial of neoadjuvant carboplatin plus docetaxel or carboplatin plus paclitaxel followed by AC in state I-III triple-negative breast cancer. Journal of Clinical Oncology, 37 (abstr 516 no. 15 suppl), 516-516. https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.516
• O'Dea Anne, Khan Meshaal, Haines HaleyIsabela, Kimler BruceF., Nye LaurenElizabeth, Sharma Priyanka, Khan QamarJ.. 2019. Fixed dose, dose-dense capecitabine in metastatic breast cancer.. JOURNAL OF CLINICAL ONCOLOGY, 37 (15 )
• Myers JS, Nesreen A, Mitchell M, Dai J, He J, Moon S, O'Dea A, Klemp J, Kurylo M, Akinwuntan A, Devos H. 2020. Pilot Feasibility Study Examining Pupillary Response During Driving Simulation as a Measure of Cognitive Load in Breast Cancer Survivors. Oncol Nurs Forum, 47 (2), 203-212
• Myers JamieS., Kahya Melike, Mitchell Melissa, Dai Junqiang, He Jianghua, Moon Sanghee, Hamilton Kevin, Valla Mary, O'Dea Anne, Klemp Jennifer, Kurylo Monica, Akinwuntan Abiodun, Devos Hannes. 2019. Pupillary response: cognitive effort for breast cancer survivors. Supportive Care in Cancer, 27 (3), 1121-1128
• Kilgore LJ, Korentager SS, Hangge AN, Amin AL, Balanoff CR, Larson KE, Mitchell MP, Chen JG, Burgen E, Khan QJ, O'Dea AP, Nye L, Sharma P, Wagner JL. 2018. Reducing Breast Cancer-Related Lymphedema (BCRL) Through Prospective Surveillance Monitoring Using Bioimpedance Spectroscopy (BIS) and Patient Directed Self-Interventions.. Annals of Surgical Oncology, 25 (10), 2948-2952
• O'Dea AnneP, Sharma Priyanka. 2018. Management of Metastatic Triple-Negative Breast Cancer. Triple-Negative Breast Cancer (1), 95-116